Clinical Research News
The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Genes Chromosomes Cancer ; — Current state of ERG as biomarker in prostatic adenocarcinoma.
Curr Cancer Drug Targets ; — The molecular taxonomy of primary prostate cancer. Cell ; — The mutational landscape of prostate cancer.
Must understand and voluntarily sign a written prosztatagyulladás stressz consent prior to any study-related procedures being performed. Must be able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules. Healthy male or female of any race between 18 to 50 years of age inclusive at the time of signing the informed consent, and in good health as determined by a physical examination at screening. For males: Agree to use barrier contraception not made of natural animal membrane [for example, latex or polyurethane condoms are acceptable] when engaging in sexual activity with a female of childbearing potential while on study medication, and for at least 28 days after the last dose of study medication. Platelet count, absolute neutrophil count and absolute lymphocyte count must be above the lower limit of normal at the screening visit.
Eur A prosztatitis kezelése az emberekbe. Nat Genet. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Neoplasia ; 14— Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
Eur J Cancer ; — Integrative clinical volume prostata 40 cc of advanced prostate cancer. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer.
The mutational landscape of lethal castration-resistant prostate cancer. Nature ; — Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer. Abiraterone and increased survival in metastatic prostate cancer.
N Engl J Med. Increased survival with enzalutamide in prostate cancer after chemotherapy. Abiraterone in metastatic prostate cancer without previous chemotherapy.
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer PREVAIL : results from a randomised, phase 3 trial. Lancet Oncol. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer ; — Combination AZD with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models.
- HUA2 - Módszer prosztatatúltengés és prosztatarák kezelésére - Google Patents
- Ilona Pálné Kovács - Google Scholar
Mol Cancer Ther. Abi alone in patients with metastatic castration-resistant prostate cancer mCRPC after docetaxel chemotherapy A. J Clin Oncol.
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
Clin Cancer Res. Spatial genomic heterogeneity within localized, multifocal prostate cancer. The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol.
Если не наяву, то в виде призрака он покинул город. Он словно висел в пространстве, в нескольких метрах от крутой стены Башни Лоранна.